Project Grant R21CA296691
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $399K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- Federal Project Grant Award Summary Virginia Commonwealth University received a $399,187 Cancer Treatment Research grant (CFDA 93.395) from the National Cancer Institute, awarded May 7, 2026, with completion targeted for April 30, 2028. The project investigates glycosaminoglycans (GAGs), specifically chondroitin sulfate and heparan sulfate, as a theragnostic approach to overcome platinum resistance in gynecological malignancies, particularly platinum-resistant ovarian cancer. The research...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $403,586 Project Grant from the National Cancer Institute (Cancer Biology Research program, CFDA 93.396) beginning August 1, 2025, and concluding July 31, 2027. The award supports research to develop codon-specific isotope labeling technology for nuclear magnetic resonance (NMR) resonance assignment. This novel methodology addresses critical obstacles in characterizing intrinsically disordered proteins (IDPs),...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760.00 to The Regents of the University of California, San Francisco under the Cancer Research Manpower program (CFDA 93.398) on July 7, 2025. This Project Grant funds research aimed at enhancing treatment outcomes for metastatic castration-resistant prostate cancer (MCRPC) through the development of novel tumor-targeted combination therapy. The primary research deliverable involves creating a single...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on dissecting the role of Carnitine Palmitoyltransferase 1C (CPT1C) in advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC) that develops following castration-resistant prostate cancer. The...
- Federal Grant Award Summary The University of Pittsburgh received a $658,492 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 18, 2026, through February 28, 2031. This award supports research and development of a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC), including castration-resistant prostate cancer adenocarcinoma (CRPC-ADENO) and neuroendocrine prostate...
- Federal Grant Award Summary Duke University received a $497,972 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on April 1, 2026, with a completion date of March 31, 2031. This research initiative focuses on developing and evaluating EZH2-targeted therapies for advanced prostate cancer, specifically addressing castration-resistant prostate cancer (CRPC). The project involves designing and testing small-molecule EZH2...
- This federal Project Grant award in the amount of $582,189.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Virginia Commonwealth University (VCU) to investigate the role of histone H2A ubiquitination and the RSF1 gene in breast cancer. The 3-year award, starting on March 1, 2024, will fund personnel, facilities, and equipment to conduct basic, translational, and clinical research aimed at advancing...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...